
    
      The study is a non-randomized clinical trial. The protocol has been approved by the Ethics
      Committee of Beijing Cancer Hospital. MRI and enhanced CT are used to evaluate the clinical
      response of the tumor. The primary endpoint is the maximal cycle of effective neoadjuvant
      chemotherapy for resectable gastric cancer.
    
  